Pfizer Inc. $PFE Position Trimmed by Stephens Inc. AR

Stephens Inc. AR trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 327,268 shares of the biopharmaceutical company’s stock after selling 35,698 shares during the period. Stephens Inc. AR’s holdings in Pfizer were worth $8,149,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC boosted its holdings in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. YANKCOM Partnership bought a new stake in Pfizer during the fourth quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the third quarter worth approximately $29,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new stake in Pfizer during the second quarter worth approximately $32,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 1.7%

Shares of Pfizer stock opened at $25.31 on Friday. Pfizer Inc. has a 12-month low of $22.45 and a 12-month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a 50 day moving average price of $26.98 and a two-hundred day moving average price of $26.19. The stock has a market capitalization of $144.25 billion, a P/E ratio of 19.32 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s payout ratio is currently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. CICC Research began coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Finally, Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.84.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.